Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Zercepac (trastuzumab) in HER2-positive advanced gastric cancer
ChiCTR2100043780Phase 4Recruiting
- Sponsor
- Affiliated Cancer Hospital of Nanjing Medical University
- Start
- May 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab in gastric adenocarcinoma and gastroesophageal adenocarcinoma, sponsored by Affiliated Cancer Hospital of Nanjing Medical University. Primary endpoint: Progression-free survival. Started May 2020; status: recruiting.
02
Drugs
03
Conditions
gastric adenocarcinomagastroesophageal adenocarcinoma
Beyond the preview
Go deeper on ChiCTR2100043780.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100043780.